Literature DB >> 23061719

The significance of ubiquitin proteasome pathway in cancer development.

Azmi Yerlikaya1, Mustafa Yöntem.   

Abstract

The ubiquitin proteasome pathway is the most significant intracellular proteolytic pathway. The target proteins are usually ubiquitinated prior to degradation by the proteasome; however, ubiquitin-independent targeting mechanisms have also been reported (e.g., the antizyme-mediated degradation of ornithine decarboxylase). Aberrations in the components of the ubiquitin proteasome pathway are commonly observed in many cancers, and uncontrolled growth of cancer cells can result either from stabilization of oncoproteins (e.g., c-jun) or increased degradation of tumor suppressor proteins (e.g., p53). In addition, due to the pleiotropic functions of the ubiquitin proteasome pathway in cells, there is great interest in developing inhibitors to specifically block this pathway for cancer treatment. This review summarizes the recent literature and several patented inventions on the ubiquitin proteasome pathway with respect to its role in cancer development and treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23061719     DOI: 10.2174/1574891x113089990033

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN: 1574-8928            Impact factor:   4.169


  13 in total

1.  An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line.

Authors:  Azmi Yerlikaya; Emrah Okur
Journal:  Cytotechnology       Date:  2019-12-20       Impact factor: 2.058

2.  The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5.

Authors:  Huan-Tian Zhang; Ling-Fei Zeng; Qing-Yu He; W Andy Tao; Zhen-Gang Zha; Chang-Deng Hu
Journal:  Biochim Biophys Acta       Date:  2015-12-02

3.  Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.

Authors:  Bekir Aras; Azmi Yerlikaya
Journal:  Oncol Lett       Date:  2016-03-16       Impact factor: 2.967

4.  Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study.

Authors:  Lianghe Jiao; Jing Wei; Jun Ye; Chuanmeng Zhang
Journal:  Dis Markers       Date:  2021-03-03       Impact factor: 3.434

5.  Gene silencing of NOB1 by lentivirus suppresses growth and migration of human osteosarcoma cells.

Authors:  Bingpeng Chen; Jingjing Liu; Dankai Wu; Yanguo Qin; Chuangang Peng; Chen Li; Jincheng Wang
Journal:  Mol Med Rep       Date:  2014-04-04       Impact factor: 2.952

6.  Inhibition on Proteasome β1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells.

Authors:  Dong Li; Yu Lu; Peng Sun; Li-Xing Feng; Miao Liu; Li-Hong Hu; Wan-Ying Wu; Bao-Hong Jiang; Min Yang; Xiao-Bo Qu; De-An Guo; Xuan Liu
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

7.  Oncodomains: A protein domain-centric framework for analyzing rare variants in tumor samples.

Authors:  Thomas A Peterson; Iris Ivy M Gauran; Junyong Park; DoHwan Park; Maricel G Kann
Journal:  PLoS Comput Biol       Date:  2017-04-20       Impact factor: 4.475

8.  Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.

Authors:  Li Yang; Jing Chen; Xiaoyan Han; Enfan Zhang; Xi Huang; Xing Guo; Qingxiao Chen; Wenjun Wu; Gaofeng Zheng; Donghua He; Yi Zhao; Yang Yang; Jingsong He; Zhen Cai
Journal:  Protein Cell       Date:  2018-02-13       Impact factor: 14.870

9.  Decreased expression of peroxiredoxin1 inhibits proliferation, invasion, and metastasis of ovarian cancer cell.

Authors:  Ming-Jun Zheng; Jing Wang; Hui-Min Wang; Ling-Ling Gao; Xiao Li; Wen-Chao Zhang; Rui Gou; Qian Guo; Xin Nie; Juan-Juan Liu; Bei Lin
Journal:  Onco Targets Ther       Date:  2018-11-02       Impact factor: 4.147

10.  Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.

Authors:  Ertan Kanbur; Ahmet Tarık Baykal; Azmi Yerlikaya
Journal:  Med Oncol       Date:  2021-08-07       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.